• April 17, 2013
Metabolic Changes Induced by Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Are Associated with Anticancer Activity in Bladder Cancer and Mesothelioma Models Especially Those That Are Deficient in Key Metabolic Protein

• June 12, 2012
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma

• February 28, 2012
Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma

• January 09, 2012
Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Combination with Docetaxel in Advanced Solid Tumors with Emphasis on Prostate Cancer

• July 28, 2011
Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma

• May 18, 2011
Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20

• May 12, 2011
Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan

• April 11, 2011
Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically with Inhibitors of Autophagy

• April 07, 2011
Transcriptional Silencing of ASS1 suggests the Potential Use of ADI-PEG 20 to Treat AML, Glioblastoma and Bladder Cancer

• March 31, 2011
FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma

• March 18, 2011
Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma

• March 15, 2011
Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer

• February 14, 2011
Polaris Group and the Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer


• June 7, 2010
Phase II Clinical Trial Results of "ADI-PEG 20" Show Efficacy in Human Metastatic Melanoma Deficient in a Key Metabolic Enzyme, and in Lymphomas in Preclinical Studies

• April 22, 2010
Multiple Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug "ADI-PEG 20"


• April 17, 2009
Polaris Collaborator to Present Research into ADI-PEG 20's Mechanism of Action at AACR 2009

• January 16, 2009
Advisory Panel Meeting Held in San Francisco: Plans for Phase 3 Trial of ADI-PEG 20 in HCC Patients Discussed

• January 15, 2009
Polaris' ADI-PEG 20 Featured in Cancer Research Article: Novel Treatment for Prostate Cancer

• January 14, 2009
Dr. Li-Tzong Chen to Present Results of Completed Asian Phase 2 Clinical Trial of ADI-PEG 20 Treatment for HCC at ASCO Gastrointestinal Cancers Symposium


• December 31, 2008
Polaris Acquires TDW Pharmaceuticals, Inc.

• December 15, 2008
USPTO Issues Notice of Allowance for Polaris' US Protein Kinase Inhibitors Patent

• October 17, 2008
Press Conference Held in Taiwan to Announce the Results of a Phase 2 Trial of ADI-PEG 20 in Advanced HCC

• October 15, 2008
Polaris' ADI-PEG 20 Featured in International Journal of Cancer Article: Novel Treatment for Pancreatic Cancer

• May 28, 2008
Polaris Acquires Equity Stake in EnzymeRx


• August 14, 2007
Ludwig Institute for Cancer Research Initiates Clinical Trial of Polaris' ADI-PEG 20 for the Treatment of Melanoma


• March 30, 2006
Polaris acquires Phoenix Pharmacologics, Inc. Intellectual Property